TW200524590A - Chemical compounds - Google Patents

Chemical compounds Download PDF

Info

Publication number
TW200524590A
TW200524590A TW093125218A TW93125218A TW200524590A TW 200524590 A TW200524590 A TW 200524590A TW 093125218 A TW093125218 A TW 093125218A TW 93125218 A TW93125218 A TW 93125218A TW 200524590 A TW200524590 A TW 200524590A
Authority
TW
Taiwan
Prior art keywords
alkyl
hydroxy
formula
compound
group
Prior art date
Application number
TW093125218A
Other languages
English (en)
Chinese (zh)
Inventor
Stuart Norman Lile Bennett
Iain Simpson
Paul Robert Owen Whittamore
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200524590A publication Critical patent/TW200524590A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW093125218A 2003-08-22 2004-08-20 Chemical compounds TW200524590A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0319759.7A GB0319759D0 (en) 2003-08-22 2003-08-22 Chemical compounds

Publications (1)

Publication Number Publication Date
TW200524590A true TW200524590A (en) 2005-08-01

Family

ID=28460130

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093125218A TW200524590A (en) 2003-08-22 2004-08-20 Chemical compounds

Country Status (8)

Country Link
US (1) US20060264494A1 (enExample)
EP (1) EP1656136A1 (enExample)
JP (1) JP2007503420A (enExample)
AR (1) AR045479A1 (enExample)
GB (1) GB0319759D0 (enExample)
TW (1) TW200524590A (enExample)
UY (1) UY28486A1 (enExample)
WO (1) WO2005018637A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
US8053603B2 (en) 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
CA2636324C (en) 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
AU2007233041B2 (en) 2006-03-31 2013-05-02 Sepracor Inc. Preparation of chiral amides and amines
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
JP5420534B2 (ja) 2007-05-31 2014-02-19 サノビオン ファーマシューティカルズ インク モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
US8680315B2 (en) 2008-06-26 2014-03-25 Prolynx, Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706810A (en) * 1970-09-15 1972-12-19 American Cyanamid Co N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides
US4692522A (en) * 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
US4668769A (en) * 1985-08-02 1987-05-26 Hoover Dennis J Oxa- and azahomocyclostatine polypeptides
US4599198A (en) * 1985-08-02 1986-07-08 Pfizer Inc. Intermediates in polypeptide synthesis
FR2601368B1 (fr) * 1986-07-08 1989-04-07 Synthelabo Derives de nitrofuranne, leur preparation et leur application en therapeutique.
DE3629545A1 (de) * 1986-08-30 1988-03-10 Bayer Ag Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung
US4751231A (en) * 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
US5863903A (en) * 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP1136071A3 (en) * 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
UY28486A1 (es) 2005-03-31
EP1656136A1 (en) 2006-05-17
WO2005018637A1 (en) 2005-03-03
AR045479A1 (es) 2005-10-26
US20060264494A1 (en) 2006-11-23
JP2007503420A (ja) 2007-02-22
GB0319759D0 (en) 2003-09-24

Similar Documents

Publication Publication Date Title
CA2709301C (en) Modulators of cystic fibrosis transmembrane conductance regulator
CN106905322B (zh) 吡咯嘧啶五元氮杂环衍生物及其应用
CA2532049C (en) Isethionate salt of a selective cdk4 inhibitor
TW200524590A (en) Chemical compounds
JP6644792B2 (ja) ベンザゼピンスルホンアミド化合物
CN101827593B (zh) 用于治疗(特别是)囊性纤维化的异噻唑并吡啶酮
CN101687883B (zh) 囊性纤维化跨膜传导调节因子的调节剂
EP1483271B1 (en) Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity
CN102958937B (zh) 作为磷酸二酯酶抑制剂的苯并二氧杂环戊烯或苯并二氧杂环庚烯杂环化合物
JP2020519596A (ja) Irak−4阻害剤として有用なチエノピリジンおよびベンゾチオフェン
JP2005526058A (ja) グリコゲンホスホリラーゼの阻害剤としての複素環式アミド誘導体
TW200901993A (en) Triazolopyridine carboxamide and triazolopyrimidine carboxamide derivatives, their preparation and their application in therapeutics
WO2010101230A1 (ja) キノキサリン化合物
JP6811233B2 (ja) Tnfアルファの修飾因子として有用な環状化合物
TW202419090A (zh) Nlrp3炎症小體抑制劑及其應用
MXPA04008612A (es) Derivados de indolamida que tienen actividad inhibitoria de glucogeno-fosforilasa.
TW200403233A (en) Chemical compounds
CN117229286A (zh) 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
US10501466B2 (en) WDR5 inhibitors and modulators
CN109641909A (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
CN107793371B (zh) 一类溴结构域识别蛋白抑制剂及其制备方法和用途
CN115466258A (zh) Atr抑制剂及其用途
US20060199966A1 (en) Indol-2-amides as glycogen phosphorylase inhibitors
CN105228609A (zh) 新的转录因子调节剂
JP2022507558A (ja) チエノピリドン誘導体のカリウム塩一水和物及びその調製方法